ePPND — Enhanced Pre- and Post-natal Development

Contact Us

Fewer models. Faster results.

We can do everything you might find in SEG II and III studies, but use fewer non-human primate models. This optimized study design can help you evaluate the functional consequences of mid to late gestational exposure. This analysis can be very insightful when assessing risk in monoclonal antibodies. 


More space for science and personalized medicine to run wild

Immuno-oncology. Biologics. Cell and gene therapies. This is the future of medicine. It’s more personalized, more complex and driving the need for highly technical nonclinical studies. To propel your personalized medicine pursuits, we’ve expanded our world-class facility in Münster, Germany. Learn more about this next-generation research facility.

Let's start a conversation

Contact Us